- Home
- AVNS vs DAWN Comparison
AVNS vs DAWN Comparison
Compare AVNS & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVNS
- DAWN
- Stock Information
- Founded
- AVNS 2014
- DAWN 2018
- Country
- AVNS United States
- DAWN United States
- Employees
- AVNS N/A
- DAWN N/A
- Industry
- AVNS Industrial Specialties
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- AVNS Health Care
- DAWN Health Care
- Exchange
- AVNS Nasdaq
- DAWN Nasdaq
- Market Cap
- AVNS 591.9M
- DAWN 624.8M
- IPO Year
- AVNS N/A
- DAWN 2021
- Fundamental
- Price
- AVNS $12.41
- DAWN $7.28
- Analyst Decision
- AVNS
- DAWN Strong Buy
- Analyst Count
- AVNS 0
- DAWN 7
- Target Price
- AVNS N/A
- DAWN $27.86
- AVG Volume (30 Days)
- AVNS 562.6K
- DAWN 1.1M
- Earning Date
- AVNS 10-29-2025
- DAWN 10-29-2025
- Dividend Yield
- AVNS N/A
- DAWN N/A
- EPS Growth
- AVNS N/A
- DAWN N/A
- EPS
- AVNS N/A
- DAWN N/A
- Revenue
- AVNS $692,500,000.00
- DAWN $187,638,000.00
- Revenue This Year
- AVNS $0.25
- DAWN $12.56
- Revenue Next Year
- AVNS $1.33
- DAWN $48.02
- P/E Ratio
- AVNS N/A
- DAWN N/A
- Revenue Growth
- AVNS 1.48
- DAWN 2190.50
- 52 Week Low
- AVNS $9.30
- DAWN $5.64
- 52 Week High
- AVNS $25.36
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- AVNS 59.41
- DAWN 54.04
- Support Level
- AVNS $11.91
- DAWN $7.18
- Resistance Level
- AVNS $13.00
- DAWN $7.58
- Average True Range (ATR)
- AVNS 0.40
- DAWN 0.26
- MACD
- AVNS 0.06
- DAWN -0.02
- Stochastic Oscillator
- AVNS 66.29
- DAWN 43.27
About AVNS Avanos Medical Inc.
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.